Y. Brian Lee
🏛️ Revolving DoorFormer Government Positions:
Legislative Intern, Rep. Doug Lamborn.
Legislative Intern, Rep. Doug Lamborn (R-CO)
🤖
AI Overview
Y. Brian Lee has appeared in 814 federal lobbying filings at Alston & Bird LLP, representing 39 clients. As a former government official, they bring insider expertise to their lobbying work — part of Washington's "revolving door." Active across 14 policy areas.
814
Total Filings
1
Firms
39
Clients
14
Issue Areas
Issue Areas
Filing History
| Year | Filings | Clients |
|---|---|---|
| 2018 | 92 | 17 |
| 2019 | 95 | 18 |
| 2020 | 102 | 20 |
| 2021 | 84 | 16 |
| 2022 | 107 | 19 |
| 2023 | 132 | 19 |
| 2024 | 128 | 22 |
| 2025 | 74 | 17 |
Firms
Alston & Bird LLP814 filings
Top Clients
American College of Gastroenterology64 filings
Dexcom, INC.60 filings
The Metrohealth System48 filings
Colorado Hospital Association47 filings
Maryland+coalition40 filings
Advanced Oxygen Therapy INC. (Aoti)35 filings
Regents of the University of Michigan34 filings
American College of Radiology34 filings
Fairview Health Services29 filings
Massachusetts Hospital Association27 filings
Trident USA Health Services26 filings
Trisalus Life Sciences25 filings
Novartis Corporation24 filings
American College of Lifestyle Medicine22 filings
Flow Therapy20 filings
Hologic, INC.17 filings
Related Analysis
Related Investigations
The Revolving Door Exposed
How former government officials become the most powerful lobbyists.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.